08
May

Alder Biopharmaceuticals stumbled into Nasdaq today, accepting a discounted $10 price for its shares as signs mount that the bloom has come off biotech’s rosy IPO boom of the past year.

…read more

Source: Does Alder’s IPO setback signal that the biotech IPO boom is ending?

    

0 No comments